Potential benefits of purified long chain omega-3 fatty acid treatment in non-alcoholic fatty liver disease (NAFLD): a potential treatment for early NAFLD in metabolic syndrome and Type 2 diabetes? Results from the WELCOME study
Main Authors: | Scorletti, E, Bhatia, B, McCormick, K, Clough, G, Nash, K, Hodson, L, Calder, P, Byrne, C |
---|---|
Format: | Journal article |
Published: |
2014
|
Similar Items
-
Effects of purified eicosapentaenoic and docosahexaenoic acids in nonalcoholic fatty liver disease: results from the Welcome* study.
by: Scorletti, E, et al.
Published: (2014) -
Advancements in the treatment of non-alcoholic fatty liver disease (NAFLD)
by: Li Rong, et al.
Published: (2023-01-01) -
The importance of the fatty acid transporter L-carnitine in non-alcoholic fatty liver disease (NAFLD)
by: Savic, D, et al.
Published: (2020) -
The Importance of the Fatty Acid Transporter L-Carnitine in Non-Alcoholic Fatty Liver Disease (NAFLD)
by: Dragana Savic, et al.
Published: (2020-07-01) -
Docosahexaenoic acid enrichment in NAFLD is associated with improvements in hepatic metabolism and hepatic insulin sensitivity: a pilot study
by: Hodson, L, et al.
Published: (2017)